Cite
HARVARD Citation
Khan, S. et al. (2021). A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Leukemia & lymphoma. 62 (7), pp. 1721-1729. [Online].